Quantinno Capital Management LP Acquires 19,281 Shares of Prestige Consumer Healthcare Inc. $PBH

Quantinno Capital Management LP raised its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 108.9% in the first quarter, Holdings Channel reports. The fund owned 36,990 shares of the company’s stock after acquiring an additional 19,281 shares during the period. Quantinno Capital Management LP’s holdings in Prestige Consumer Healthcare were worth $2,192,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Dean Capital Management raised its holdings in Prestige Consumer Healthcare by 65.8% during the 1st quarter. Dean Capital Management now owns 67,798 shares of the company’s stock worth $4,018,000 after buying an additional 26,899 shares during the period. Rice Hall James & Associates LLC boosted its holdings in shares of Prestige Consumer Healthcare by 4.2% in the first quarter. Rice Hall James & Associates LLC now owns 521,622 shares of the company’s stock valued at $30,917,000 after buying an additional 21,022 shares during the period. Wealth Alliance LLC bought a new stake in shares of Prestige Consumer Healthcare during the first quarter worth $250,000. Morningstar Investment Management LLC increased its position in shares of Prestige Consumer Healthcare by 118.0% during the first quarter. Morningstar Investment Management LLC now owns 33,410 shares of the company’s stock worth $1,980,000 after acquiring an additional 18,082 shares in the last quarter. Finally, Inceptionr LLC acquired a new stake in shares of Prestige Consumer Healthcare during the first quarter worth $433,000. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

PBH opened at $52.79 on Tuesday. The business’s 50-day simple moving average is $48.96 and its 200 day simple moving average is $55.91. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $71.07. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The firm has a market capitalization of $2.50 billion, a PE ratio of 14.79, a PEG ratio of 1.70 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The firm had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. During the same quarter in the previous year, the firm earned $0.90 EPS. The business’s quarterly revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PBH has been the topic of several research reports. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Zacks Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Finally, Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).